AstraZeneca PLC's Fiscal Year is From January To December - All Figures are in USD, Billions.
The item "Net-Income-From-Continuing-Operations" stands at 9.40 Billion United States Dollars for the trailing twelve months (TTM) period ending 09/30/2025, the highest value at least since 06/30/2017, the period currently displayed.
AstraZeneca PLC's third quarter result of 2.54 Billion USD for the item "Net Income From Continuing Operations" represents an increase of 3.55 percent compared to it's second quarter result.
Also, AstraZeneca PLC's third quarter result of 2.54 Billion USD for the item "Net Income From Continuing Operations" represents an increase of 76.90 percent compared to it's third quarter result of last year.
Looking again at the trailing twelve months series (TTM), AstraZeneca PLC's third quarter result of 9.40 Billion USD for the item "Net Income From Continuing Operations" represents an increase of 13.27 percent compared to it's second quarter result.
Regarding the One-Year-Change of the series, the current value constitutes an increase of 2.90 Billion United States Dollars compared to the value the year prior.
The 1 year change is 2.90 Billion United States Dollars.
The 3 year change is 7.36 Billion United States Dollars.
The 5 year change is 6.99 Billion United States Dollars.
| Logo | Name | Market Cap (USD) |
|---|---|---|
![]() | Eli Lilly and Company - Net Income From Continuing Operations | 905,699,262,464.00 |
![]() | Johnson & Johnson - Net Income From Continuing Operations | 486,508,953,600.00 |
![]() | AbbVie Inc - Net Income From Continuing Operations | 399,570,305,024.00 |
![]() | Roche Holding AG - Net Income From Continuing Operations | 317,433,206,677.55 |
![]() | Novartis AG - Net Income From Continuing Operations | 255,096,620,580.91 |